Asia-Pacific Breast Cancer Therapeutics Markets Report

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
716
Asia-Pacific Breast Cancer Therapeutics Markets Report 2017-2024

Dublin, June 05, 2018 (GLOBE NEWSWIRE) -- The "Breast Cancer Therapeutics in Asia-Pacific Markets to 2024 - Growth Driven by Increasing Uptake of Targeted Therapies and Rising Prevalence" report has been added to ResearchAndMarkets.com's offering. Breast Cancer Market in Asia Pacific Valued at Just Over $2 Billion in 2017, and is Expected to Grow at a CAGR of Around 11.9% to Reach About $4.75 Billion in 2024

The major factors that are expected to drive the market include increases in diagnosed prevalence and the annual cost of therapy (ACoT) due to higher uptake of costlier therapies. HER2-positive breast cancer is an aggressive disease, and historically has had a worse overall survival (OS) than HER2-negative disease, which is considered to be less aggressive. The current marketed drug landscape in breast cancer includes a mix of targeted therapies, chemotherapies, and hormonal agents.

Metastatic breast cancer is not considered a curable disease, and in the course of therapy patients can receive up to three lines of endocrine agents and four or more lines of chemotherapy, as well as targeted therapies for earlier lines of therapy often in no particular sequence. Hormone therapy is the mainstay of treatment for patients with HR-positive disease, but triple-negative breast cancer (TNBC) patients who lack HR expression are normally treated with generic chemotherapies.

Key Topics Covered:

1 Table of Contents 2 Introduction 3 Marketed Products

3.1 Overview

  • Herceptin (trastuzumab) - Roche/Genentech
  • Perjeta (pertuzumab) - Roche/Genentech
  • Kadcyla (ado-trastuzumab emtansine) - Roche/Genentech
  • Tykerb/Tyverb (lapatinib ditosylate monohydrate) - Novartis
  • Ibrance (palbociclib) - Pfizer
  • Kisqali (ribociclib) - Novartis
  • Halaven (eribulin mesylate) - Eisai
  • Avastin (bevacizumab) - Roche/Genentech
  • Afinitor (everolimus) - Novartis
  • Abraxane (Nab-Paclitaxel) - Celgene
  • Ixempra (ixabepilone) - R-Pharm
  • Doxil/Caelyx (pegylated liposomal doxorubicin) - Johnson & Johnson
  • Faslodex (fulvestrant) - AstraZeneca
  • Tamoxifen
  • Aromatase Inhibitors (AIs)

3.2 Comparative Efficacy and Safety of Marketed Products 4 Pipeline Analysis 4.1 Overview 4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type 4.3 Promising Pipeline Molecules

  • Nerlynx (Neratinib) - Puma Biotechnology
  • Verzenio (abemaciclib) - Eli Lily
  • Lynparza (olaparib) - AstraZeneca
  • Talazoparib - Pfizer/BioMarin
  • Keytruda (pembrolizumab) - Merck & Co.
  • Tecentriq (atezolizumab) - Roche
  • Taselisib - Genentech
  • Alpelisib - Novartis
  • Margetuximab - MacroGenics
  • OBI-822/821 (adagloxad simolenin) - OBI Pharma
  • Utidelone (UTD-1) - Beijing Biostar Technologies
  • Pyrotinib (HTI1001/SHR1258) - Jiangsu Hengrui Medicine
  • Ipatasertib (RG-7440/GDC-0068) - Array Biopharma/Genentech
  • Epidaza (Tucidinostat/ HBI8000/ CS055) - Chipscreen Biosciences
  • BAT8001 - Bio-Thera Solutions

4.4 Comparative Efficacy and Safety of Pipeline Products 4.5 Product Competitiveness Framework 5 Clinical Trial Analysis 5.1 Failure Rate 5.2 Clinical Trial Duration 5.3 Clinical Trial Size 5.4 Competitive Clinical Trials Metrics Analysis 6 Multi-scenario Forecast 7 Drivers and Barriers

7.1 Drivers

  • Increased Uptake of Targeted and Combination Therapies for Breast Cancer
  • Increasing Aging Population and Incident Cases of Breast Cancer
  • Prolonged Treatment Duration
  • Expansion of Branded Therapies into the Early Disease Regimen
  • Diversified Healthcare Reform and Insurance System to Boost Market Growth

7.2 Barriers

  • Usage of Surgical Therapies at Early Stage Reduces Drug Treatment Rate
  • Multiple Drugs to Lose Patent Protection in the Forecast Period
  • Delayed Presentation of Symptoms, Lack of Access and Awareness to Hamper Proper Treatment
  • High Level of Competition
  • Drug Pricing Reforms
  • Problems with the Reimbursement of Premium-Priced Therapeutics will Limit their Uptake

8 Deals and Strategic Consolidations 8.1 Licensing Deals 8.2 Co-development Deals

Companies Mentioned

  • Array Biopharma
  • AstraZeneca
  • Beijing Biostar Technologies
  • Bio-Thera Solutions
  • BioMarin
  • Celgene
  • Chipscreen Biosciences
  • Eisai
  • Eli Lily
  • Genentech
  • Johnson & Johnson
  • MacroGenics
  • Merck & Co.
  • Novartis
  • OBI Pharma
  • Pfizer
  • Puma Biotechnology
  • R-Pharm
  • Roche
  • iangsu Hengrui Medicine

For more information about this report visit https://www.researchandmarkets.com/research/d...cific?w=12

CONTACT: ResearchAndMarkets.com Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Genomics, Breast Cancer Drugs

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Dickinson Brands Celebrates Witch Hazel Legacy with Event

Updated Category News Views 9

Witch Hazel's Timeless Appeal You don’t get to celebrate over one and a half centuries of a product without doing something right. Dickinson Brands Inc. is throwing a bash worth noticing as they mark the sixth annual National Witch Hazel Day on October 21st. It’s a head-nod to the versatile witch hazel, a product that’s been part of New England's heritage since the...

Continue Reading
AEVEX Facing Class Action: Deadline Looms for Investors

Updated Category News Views 10

The Clock is Ticking for AVEX Investors News flash, folks: If you bought into AEVEX Corp. (NYSE: AVEX) between mid-April and early June this year, you might have a legal gold mine on your hands—or at least a shot to join a class action that could knock some dollars back into your pocket. Mark it on your calendar—October 20, 2026, is the last call to toss your hat in...

Continue Reading
GELITA Showcases Collagen Innovations at SupplySide 2026

Updated Category News Views 11

Collagen Solutions Front and Center First up, a little chat about collagen might be in order. For folks not tied into the science side, it sounds like a trendy wellness potion. But here comes GELITA at SupplySide Global 2026, showing it's the real McCoy. Nestled in Booth #4565, they're laying out a spread of next-gen collagen innovations aimed at everything from wound...

Continue Reading
First Student Reduces Collisions by 63% with HALO Tech

Updated Category News Views 0

Making Every School Bus Ride Safer Here's some good news in the world of transportation, especially if you're keen on keeping kids safe on the daily school bus run. First Student's HALO™ Connected Transportation Platform claims it made a significant dent in reducing accidents—specifically, a 63% cut in forward collision risk. It's a big promise when you're talking...

Continue Reading
Spooky Suds: House of Horror Meets El Car Wash

Updated Category News Views 3

A Haunted Wash Awaits Miami Drivers Picture this: you're cruising down West Flagler on a regular Wednesday evening, but tonight, you're not just rolling in for a rinse. Nope, this Wednesday night, the wash tunnel at El Car Wash gets downright spooky. It's getting a haunted house makeover with scare actors from the House of Horror. When a Car Wash Becomes a Haunted...

Continue Reading
Ama La Vida's New Coaching: More Than a Financial Plan

Updated Category News Views 3

Breaking the Retirement Myth Retirement ain't just about sailing off into the sunset with a fat wallet. What happens when the honeymoon period of the "golden years" ends and you're left pacing the floorboards, unsure of what comes next? Enter Ama La Vida's fresh approach to retirement coaching, tackling the side of retirement that's rarely spoken about: identity,...

Continue Reading
2GenPen & LordCap Team Up: Game-Changer in ABS?

Updated Category News Views 5

New Kids on the Structured Credit Block? Well, it looks like we're in for a ride with 2GenPen teaming up with Lord Capital to shake up the asset-backed securities (ABS) world. They're strutting their stuff by launching a strategic collaboration to boost credit analysis. Think of it as a power-up for ABS transactions—because nobody loves a murky credit rating. The Heart...

Continue Reading
De¹ Unveils Tokenization Model on BNB Chain

Updated Category News Views 2

De¹'s Bold Move into Enhanced Digital Finance Just when you thought the financial landscape couldn’t get any more complex, De¹ steps into the ring with its Tokenized Asset World on the BNB Chain—a move that's stirring the pot of tokenized finance in more ways than one. For old-school investors who thrive on waving outlandish stock bets, this crypto narrative is a...

Continue Reading
Community Heritage Financial Declares Q3 2026 Dividend

Updated Category News Views 0

Dividend Declared Amidst Challenging Times There's nothing quite like the ringing of a cash register, and for Community Heritage Financial, Inc. (OTCID: CMHF), that's what an $0.08 per share dividend feels like. Declared for the third quarter of 2026, this payout is set to line the pockets of shareholders who made the cut by October 30, 2026. The folks waiting for their...

Continue Reading
Chicago Scenic Studios’ Equipment Up for Grabs in Auction

Updated Category News Views 13

A Peek into the Sale: What's on the Block? Get that coffee brewing and settle in, because we've got to unpack some interesting stuff happening with Chicago Scenic Studios. This isn't just any Craigslist decampment—Integra Asset Solutions is rolling out an online auction come October 27 that’ll have equipment-savvy investors’ ears perking up like they just snagged a...

Continue Reading

Top 5 Most Recently Viewed Articles

Analyzing SLB's Market Dynamics and Investor Sentiment Trends

Updated Category News Views 122

Understanding SLB's Market Position SLB's short percent of float has decreased by 9.27% since its last report, revealing important trends in investor sentiment. Recently, the company disclosed that it has 61.95 million shares sold short, amounting to 4.6% of the total shares available for trading. Analyzing this information provides valuable insight into how traders...

Continue Reading
Insight into Debtor Composition for Bond Issuance Announcements

Updated Category News Views 97

Understanding Debtor Composition in Bonds In the dynamic world of financial markets, understanding the debtor composition is crucial for investors and stakeholders alike. Recently, Jyske Realkredit released data on the debtor composition related to its bonds, as mandated by the Capital Markets Act. What is Debtor Composition? Debtor composition refers to the breakdown of...

Continue Reading
Valid Eval Awarded NASA Contract to Enhance Evaluation Systems

Updated Category News Views 135

Valid Eval Receives SBIR Contract from NASA Valid Eval, recognized for its innovative secure SaaS platform that facilitates complex group evaluations, has achieved a significant milestone by securing a Phase III Small Business Innovation Research (SBIR) contract from NASA. This contract marks a noteworthy step forward in managing NASA's SBIR/STTR program applicant...

Continue Reading
Klaviyo's Bright Future: Stifel Sees Growth and Potential

Updated Category News Views 42

Stifel Gives Klaviyo a Buy Rating Klaviyo (NYSE: KVYO) has made its mark in the marketing automation sector, and recently, Stifel has recognized this by initiating coverage with a Buy rating. This comes with a targeted price set at $45, highlighting the confidence in Klaviyo’s capacity to harness the burgeoning digital marketing environment. Stifel analysts point to the...

Continue Reading
Jay-Z's Inspiring Journey to Wealth and Emotional Growth

Updated Category News Views 435

Jay-Z's Evolution: From Survival to Emotional Intelligence Shawn Carter, widely known as Jay-Z, has emerged as a beacon of inspiration, particularly after being recognized by prominent investor Warren Buffett as “the guy to learn from.” This iconic rapper's journey, deeply rooted in his Brooklyn upbringing, exemplifies a profound transformation and growth that extends...

Continue Reading